Iceland· IS-EU/1/16/1142/009-012
Parsabiv
A etelcalcetide product containing etelcalcetidum inn hýdróklóríð, registered in Iceland by Amgen Europe B.V.*. The same ATC class is registered in 14 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Etelcalcetide is registered in 14 of 19 countries.
Countries holding a registration under ATC H05BX04 (etelcalcetide), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 10 of them publish a price we can compare per daily dose
Etelcalcetide · ATC H05BX04
14 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Etelcalcetidum INN hýdróklóríð
- Manufacturer
- Amgen Europe B.V.*
- Country
- Iceland (IS)
- ATC code
- H05BX04
- ATC class
- Etelcalcetide
- Defined daily dose
- 2.1 mg, P
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
20 interactions on record for etelcalcetide.
Graded by severity as the source publishes them — 19 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Etelcalcetide · interactions on record
20 records
- 19 severe
- 1 moderate
Most severe, free to view
- FurosemideC03CA01severe
- BumetanideC03CA02severe
- TorasemideC03CA04severe
- Etacrynic acidC03CC01severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Etelcalcetide in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaPARSABIVAmgen Europe B.V., Breda
- BelgiumParsabiv 10 mgAmgen Europe
- SpainPARSABIV 10 MG SOLUCION INYECTABLEAmgen Europe B.V.
- PolandParsabivAmgen Europe B.V.
- SwedenParsabiv 10 mg Injektionsvätska, lösningAmgen Europe B.V.
- SwitzerlandParsabiv 10.0 mg, InjektionslösungAmgen Switzerland AG
- FinlandParsabivAmgen Europe B.V.
- FrancePARSABIV 10 mg, solution injectableAMGEN EUROPE
Authorised across Europe · EMA
The same active substance is authorised in 1 EEA country. Names it is sold under:
- Norway · Parsabiv
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ed1a5d59-b2a4-45db-bdf4-ba9b164bfc4a GET /v1/drugs/ed1a5d59-b2a4-45db-bdf4-ba9b164bfc4a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Stungulyf, lausn",
"source": "lyfjastofnun",
"atc_raw": "H05BX04",
"marketed": false,
"strength": "10 mg",
"ma_number": "EU/1/16/1142/009-012",
"substance": "Etelcalcetidum INN hýdróklóríð",
"other_info": null,
"legal_status": "(R) Lyfseðilsskylt",
"ma_issued_serial": "42685"
}See everything about etelcalcetide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.